- In March 2024, Iridex Corporation, a leading provider of laser-based medical systems for ophthalmology, launched its next-generation Cyclo G6® Laser System with updated probe designs aimed at improving treatment precision for angle-closure glaucoma. The system enhances safety and efficacy in reducing intraocular pressure, particularly in chronic PACG cases. This development reinforces Iridex’s commitment to advancing non-invasive glaucoma therapies and improving patient outcomes through precision technology in laser interventions
- In February 2024, Santen Pharmaceutical Co., Ltd. announced a new clinical collaboration to evaluate combination therapy options involving its established glaucoma eye drops and laser trabeculoplasty for managing chronic primary angle-closure glaucoma in Asian populations. This collaboration reflects a growing focus on multimodal treatment strategies tailored to regional disease burdens and highlights the role of pharmaceutical innovation in chronic glaucoma care
- In January 2024, Alcon Inc. unveiled a significant expansion of its Glaucoma Surgical Training Program across Asia-Pacific, focusing on techniques for managing angle-closure glaucoma through minimally invasive glaucoma surgery (MIGS). The initiative aims to upskill ophthalmic surgeons in underserved markets, improving access to advanced treatment methods and reinforcing Alcon’s leadership in surgical ophthalmology solutions
- In October 2023, New World Medical, Inc., a U.S.-based glaucoma device company, received expanded regulatory approvals for its Ahmed ClearPath drainage devices in several Latin American countries for the treatment of advanced PACG. These devices offer a long-term solution for patients with elevated intraocular pressure unresponsive to conventional therapies. The expansion reflects New World Medical’s global strategy to address unmet needs in glaucoma management
- In September 2023, Ellex (a Lumibird Group company) introduced enhancements to its SLT (Selective Laser Trabeculoplasty) systems, improving energy delivery and targeting for early-stage primary angle-closure cases. The new features offer ophthalmologists greater control and reduce procedural variability, supporting more effective pressure reduction in patients with narrow angles or early closure. This innovation underscores the industry’s focus on optimizing non-invasive treatment options.
